Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 31.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 17,707 shares of the specialty pharmaceutical company's stock after selling 8,026 shares during the quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main's holdings in Jazz Pharmaceuticals were worth $2,181,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JAZZ. IFP Advisors Inc acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at $25,000. Quadrant Capital Group LLC increased its holdings in shares of Jazz Pharmaceuticals by 97.1% in the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after purchasing an additional 101 shares during the period. CoreFirst Bank & Trust purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth about $28,000. Allianz SE acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $29,000. Finally, Jones Financial Companies Lllp boosted its position in Jazz Pharmaceuticals by 75.1% in the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after buying an additional 130 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ traded down $0.67 during trading on Tuesday, reaching $102.91. The company had a trading volume of 781,022 shares, compared to its average volume of 837,276. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The stock has a 50-day moving average price of $118.23 and a two-hundred day moving average price of $122.25. The stock has a market capitalization of $6.34 billion, a PE ratio of 14.49, a price-to-earnings-growth ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The firm had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. During the same quarter last year, the business posted $2.68 EPS. The firm's revenue was down .5% compared to the same quarter last year. As a group, sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current year.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the sale, the executive vice president now owns 33,318 shares of the company's stock, valued at approximately $4,826,778.66. This represents a 10.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Seamus Mulligan purchased 1,621 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was acquired at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the acquisition, the director now directly owns 101,621 shares of the company's stock, valued at $10,466,963. This trade represents a 1.62% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 28,236 shares of company stock worth $3,956,190 in the last three months. 4.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. Piper Sandler reissued an "overweight" rating and set a $147.00 target price (down previously from $176.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, May 7th. StockNews.com downgraded Jazz Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, May 7th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a report on Thursday, March 6th. Finally, Robert W. Baird dropped their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus price target of $182.79.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.